Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–56.

Article  CAS  PubMed  Google Scholar 

Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46: 101102.

Article  CAS  PubMed  Google Scholar 

McIntosh CH, Demuth HU, Pospisilik JA, Pederson R. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept. 2005;128(2):159–65.

Article  CAS  PubMed  Google Scholar 

Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773–86.

Article  CAS  PubMed  Google Scholar 

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.

Article  CAS  PubMed  Google Scholar 

Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414–25.

Article  CAS  PubMed  Google Scholar 

Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487–93.

Article  CAS  PubMed  Google Scholar 

Goldenberg RM, Teoh H, Verma S. Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data. Curr Opin Cardiol. 2023;38(6):539–45.

Article  PubMed  Google Scholar 

Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(9):623–33.

Article  CAS  PubMed  Google Scholar 

Wang Q, Chen K, Liu R, Zhao F, Gupta S, Zhang N, et al. Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. PLoS One. 2010;5(9): e12734.

Article  PubMed  PubMed Central  Google Scholar 

Cui Q, Liao Y, Jiang Y, Huang X, Tao W, Zhou Q, et al. Novel GLP-1 analog supaglutide improves glucose homeostasis in diabetic monkeys. J Endocrinol. 2021;248(2):145–54.

Article  CAS  PubMed  Google Scholar 

Ren L, Cui Q, Liu W, Wang L, Liao Y, Feng Y, et al. Novel GLP-1 analog supaglutide stimulates insulin secretion in mouse and human islet beta-cells and improves glucose homeostasis in diabetic mice. Front Physiol. 2019;10:930.

Article  PubMed  PubMed Central  Google Scholar 

Specific instructions for the use of organ dysfunction templates. https://ctep.cancer.gov/protocoldevelopment/docs/hepatic_dysfunction_template_v4.docx.

Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090–101.

Article  CAS  PubMed  Google Scholar 

Seino Y, Terauchi Y, Osonoi T, Yabe D, Abe N, Nishida T, et al. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab. 2018;20(2):378–88.

Article  CAS  PubMed  Google Scholar 

Sengoku T, Ishizaki T, Goto Y, Iwao T, Ohtera S, Sakai M, et al. Prevalence of type 2 diabetes by age, sex and geographical area among two million public assistance recipients in Japan: a cross-sectional study using a nationally representative claims database. J Epidemiol Community Health. 2022;76(4):391–7.

Article  PubMed  Google Scholar 

Geiser JS, Heathman MA, Cui X, Martin J, Loghin C, Chien JY, et al. Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: analyses of data from clinical trials. Clin Pharmacokinet. 2016;55(5):625–34.

Article  CAS  PubMed  Google Scholar 

Petri KCC, Ingwersen SH, Flint A, Zacho J, Overgaard RV. Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes. Diabetes Obes Metab. 2018;20(9):2238–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schneck K, Urva S. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT Pharmacomet Syst Pharmacol. 2024;13(3):494–503.

Article  CAS  Google Scholar 

Guan Y, Ly N, Li J, Arends RH. Population pharmacokinetics of cotadutide in subjects with type 2 diabetes. Clin Pharmacokinet. 2022;61(6):833–45.

Article  CAS  PubMed  Google Scholar 

Overgaard RV, Delff PH, Petri KCC, Anderson TW, Flint A, Ingwersen SH. Population pharmacokinetics of semaglutide for type 2 diabetes. Diabetes Ther. 2019;10(2):649–62.

Article  CAS  PubMed  PubMed Central  Google Scholar